IDH1 and cholangiocarcinoma: In this context, a phase 3, randomized, double-blind study (ClarIDHy) randomized (2:1) 185 patients with IDH1-mutant cholangiocarcinoma, previously treated with up to 2 treatment regimens, to receive a mutated IDH1 inhibitor, ivosidenib (AG-120), or placebo [50].